DUBAI, UAE, May 31, 2017 /PRNewswire/ --
Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions,
The WHO estimates that over 360 million people - over 5 per cent of the world's population - live with disabling hearing loss, 32 million of whom are children. With prevalence rates rising, the global cost of unaddressed hearing loss has recently been estimated at $750 billion per year.
The WHA resolution outlines practical, cost effective steps, starting with awareness, hearing screening programs at key stages of life, and making assistive hearing technologies, such cochlear implants, more accessible to those who need them.
Chris Smith, Cochlear CEO & President, welcomed the leadership of government health policy leaders worldwide.
"This resolution gives hope to people with disabling hearing loss, no matter their age, or where they're from," said Smith. "In some countries, children with hearing loss are excluded from schooling. Adults with hearing loss are unable to find work or fulfil their potential, and older adults face costly health problems when hearing loss is unaddressed."
"The jury is no longer out - deafness and hearing loss have been found to be a significant global public health issue and the world's leading health policy-setting body has said it's time to act. At Cochlear, we are driven by our mission to improve the lives of people with hearing loss, and as a hearing health expert, we join with other stakeholders to play our part in tackling this global health issue."
"This resolution is a major milestone and if implemented, has the potential to alleviate the enormous burden experienced by millions of people and many societies."
The resolution sets out a number of critical steps for addressing the impact of deafness and hearing loss, including:
Many of the causes of hearing loss can be avoided through public health measures; it is estimated that 60 per cent of hearing loss in children can be prevented. This figure is higher (75 per cent) in low and middle-income countries than in high-income countries (49 per cent).
At present, it is estimated that hearing aid production meets only 10 per cent of the global need. The benefits of cochlear implants are widely acknowledged for children,, and evidence shows that cochlear implantation for adults is an effective intervention for a much wider group of candidates than had previously been thought.
About Cochlear Limited (ASX: COH)
Cochlear is the global leader in implantable hearing solutions. The company has a global workforce of 3,000 people and invests more than AUD$100 million a year in research and development. Products include hearing systems for cochlear, bone conduction and acoustic implants. Over 450,000 people of all ages, across more than 100 countries, now hear because of Cochlear. http://www.cochlear.com
About Cochlear Implants
The trade name for cochlear implants manufactured by Cochlear is the Cochlear™ Nucleus® series cochlear implants. The approved indications for the use of Cochlear Nucleus series cochlear implants is the treatment of moderate to profound hearing loss. Please seek advice from your medical practitioner or health professional about treatments for hearing loss. They will be able to advise on a suitable solution for the hearing loss condition. All products should be used only as directed by your medical practitioner or health professional. Not all Cochlear products are available in all countries. Please contact your local Cochlear representative here: http://www.cochlear.com/wps/wcm/connect/intl/contact/global-offices
SOURCE Cochlear Middle East FZ-LLC
Subscribe to our Free Newsletters!
Benign prostatic hyperplasia or enlarged prostate is a noncancerous condition observed in men above ...
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...
Hashimoto's thyroiditis is an autoimmune disorder of the thyroid causing hypothyroidism. Synthetic ...View All